Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles vaccine + respiratory syncytial virus vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The measles vaccine + respiratory syncytial virus (RSV) vaccine is an investigational combination vaccine candidate designed to provide dual protection against both measles and RSV infections. The most prominent version of this combination utilizes a recombinant, live-attenuated measles virus (MV) platform (typically the Schwarz strain) as a viral vector to express the fusion (F) protein of the respiratory syncytial virus. By leveraging the established safety and high immunogenicity of the measles vaccine, the candidate induces both humoral and cellular immune responses against the measles virus and the RSV F protein. This approach is particularly targeted at the pediatric population, where both pathogens represent significant causes of morbidity and mortality. The measles vector replicates within the host, ensuring prolonged antigen presentation and the induction of robust T-cell memory.
- Other names
- Measles-RSV combination vaccineRecombinant measles virus-RSV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on measles vaccine + respiratory syncytial virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles vaccine + respiratory syncytial virus vaccine.